Acrokeratosis Neoplastica Medication
- Author: Cary Chisholm, MD; Chief Editor: William D James, MD more...
Medication Summary
The goal of pharmacotherapy in acrokeratosis neoplastica is to improve scaly lesions, reduce morbidity, and prevent complications.
Antipsoriatic Agent, Systemic
Acitretin (Soriatane)
Metabolite of etretinate and related to both retinoic acid and retinol (vitamin A). Mechanism of action unknown. However, thought to exert therapeutic effect by modulating keratinocyte differentiation, keratinocyte hyperproliferation, and tissue infiltration by inflammatory cells.
Antipsoriatic Agent, Topical
Salicylic acid topical
By dissolving the intercellular cement substance, salicylic acid produces desquamation of the horny layer of skin while not affecting structure of viable epidermis.
Hydrate skin and enhance effects of medication by soaking affected area in warm water for 5 min prior to use. Remove any loose tissue with brush, wash cloth, or emery board and dry thoroughly. Improvement should generally occur in 1-2 wk.
Topical Skin Product
Calcipotriene (Dovonex)
Synthetic vitamin D-3 analog that regulates skin cell production and development. Inhibits epidermal proliferation, promotes keratinocyte differentiation, and has immunosuppressive effects on lymphoid cells. Used in the treatment of moderate plaque psoriasis. Use 0.005% cream, ointment, or solution.
Dietary Supplements
Cholecalciferol (Delta-D, Vitamin D-3)
Stimulates absorption of calcium and phosphate from small intestine and promotes release of calcium from bone into blood. Antiproliferative and anti-inflammatory effects on skin.
Corticosteroids
Betamethasone topical (Diprolene, Betatrex)
For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Mineral, Parenteral
Zinc
Cofactor for more than 70 types of enzymes. Plays a role in many metabolic processes. Higher requirement may be indicated in pregnancy.
Use the sulfate or gluconate zinc salts. Zinc sulfate 4.4 mg = 1 mg of elemental zinc. Zinc gluconate 7.1 mg = 1 mg of elemental zinc.
Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg. Mar-Apr 2007;11(2):78-83. [Medline].
Karabulut AA, Sahin S, Sahin M, Eksioglu M, Ustün H. Paraneoplastic acrokeratosis of Bazex (Bazex's syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol. Dec 2006;33(12):850-4. [Medline].
Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg. Mar-Apr 2007;11(2):78-83. [Medline].
Valdivielso M, Longo I, Suarez R, Huerta M, Lazaro P. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol. May 2005;19(3):340-4. [Medline].
Crucitti A, Feliciani C, Grossi U, La Greca A, Porziella V, Giustacchini P. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol. Dec 20 2009;27(36):e266-8. [Medline].
Ljubenovic MS, Ljubenovic DB, Binic II, Jankovic AS, Jovanovic DL. Acrokeratosis paraneoplastica (Bazex syndrome). Indian J Dermatol Venereol Leprol. May-Jun 2009;75(3):329. [Medline].
Chapireau D, Adlam D, Cameron M, et al. Paraneoplastic syndromes in patients with primary oral cancers: A systematic review. Br J Oral Maxillofacial Surg. 2009;epub ahead of print.
da Rosa ACM, Pinto GM, Bortoluzzi JS, et al. Three simultaneous paraneoplastic manifestations (ichthyosis acquisita, Bazex syndrome, and Leser-Trelat sign) with prostate adenocarcinoma. J Am Acad Dermatol. 2009;61:538-540.
Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma. J Am Acad Dermatol. Dec 2006;55(6):1103-5. [Medline].
Chave TA, Bamford WM, Harman KE. Acrokeratosis paraneoplastica associated with recurrent metastatic thymic carcinoma. Clin Exp Dermatol. Jul 2004;29(4):430-2. [Medline].
Ali M, Keir M, Dodd H, Cerio R. Flexural Bazex syndrome associated with tonsillar adenocarcinoma. J Drugs Dermatol. Sep-Oct 2004;3(5):557-9. [Medline].
Cabanillas M, Perez-Perez L, Sanchez-Aguilar D, Fernandez-Redondo V, Toribio J. [Acrokeratosis paraneoplastica with bullous lesions associated with esophageal squamous cell carcinoma]. Actas Dermosifiliogr. Apr 2006;97(3):196-9. [Medline].
Fasanmade A, Farrell K, Perkins CS. Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm. Br J Oral Maxillofac Surg. Mar 2009;47(2):138-9. [Medline].
Medenica L, Gajic-Veljic M, Škiljevic D, et al. Acrokeratosis paraneoplastica Bazex syndrome associated with eophageal squamocellular carcinoma. Vojnosanit Pregl. 2008;65:485-487.

